A bladder-shaped icon

The future of
bladder cancer

Explore what's next in care
A question mark-shaped icon

Did you know?
For patients and caregivers

Learn clinical terms that can help you better understand treatment
An icon of 2 arrows connected at the bottom

A pathway toward a
more tolerable option

Take a closer look at a critical regulator in bladder cancer
An arrowhead icon that points to the right

The challenges in making
treatment decisions

Navigate the evolving therapeutic options

A vision for the future of bladder cancer

Non-muscle invasive bladder cancer (NMIBC) therapy has made great strides in the past few years. However, with high recurrence and progression rates, there’s still room to grow.1

Take a closer look at an opportunity to advance care
A urologist speaks with bladder cancer patient and caregiver inside her office Not an actual patient-physician interaction.

Did you know?

For patients and caregivers

Understanding how a therapy is evaluated can help you and your doctor decide on the right treatment plan for you.

Learn the clinical terms that measure a therapy’s effectiveness and safety

A critical pathway in bladder cancer

Science has uncovered a key regulator in the underlying biology of bladder cancer.2

Get to know the Rb-E2F pathway

Complexity of treatment decisions

Radical cystectomy. BCG. Novel bladder-sparing agents. Clinical trial enrollment. With a growing number of treatment options for high-risk NMIBC, making the right decision can be complex and challenging.

Explore the therapeutic landscape
A uro-oncologist looks out a window as if considering bladder cancer treatment options Not an actual physician.
References: 1. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-477. 2. Wang J-P, Jiao Y, Wange C-Y, et al. Rb knockdown accelerates bladder cancer progression through E2F3 activation. Int J Oncol. 2017;50:149-160.
Contact
an MSL